Fig. 4. Fc receptor engagement supports tiragolumab surrogate efficacy and ability to remodel the tumour microenvironment in mice.
a, Growth of CT26 tumours in syngeneic BALB/c mice under various treatments. Data are representative of two or more independent experiments with n = 10 mice in each group. b–d, Heat maps of the expression of selected genes across different treatments in tumour macrophages and monocytes combined (b; left), tumour CD8+ T cells combined (c; left) and tumour CD4+ Treg cells (d; left). Volcano plots showing gene expression for anti-PD-L1 + anti-TIGIT IgG2b versus anti-PD-L1 (middle), and anti-PD-L1 + anti-TIGIT IgG2a versus anti-PD-L1 (right) in tumour macrophages and monocytes combined (b), tumour CD8+ T cells combined (c) and tumour CD4+ Treg cells (d). For the volcano plots in b–d, the broken y axis was used to make the y-axis range comparable and for better comparison between treatments. P values were calculated using two-tailed Wilcoxon rank-sum tests.